GHK-Cu Skin Rejuvenation Protocol

Studies examining GHK-Cu for dermal applications have used concentrations ranging from 1 ng/mL to 1 µg/mL in in vitro fibroblast models, and doses of 1–5 mg/kg in animal wound healing studies. As reported in the literature, subcutaneous administration has been tested in rodent skin repair models.

All dosing figures are drawn from published research and are provided for research reference only. They do not constitute medical advice or dosing recommendations for human use.

Dermal application studies typically run for 4–12 weeks to observe measurable changes in collagen density and skin thickness. In vitro studies use acute exposure periods of 24–72 hours. Animal wound healing studies measure closure at 7, 14, and 21 days.

Researchers monitoring GHK-Cu effects in skin aging models have measured: serum copper levels (to confirm chelated copper delivery); collagen I and III via dermal biopsy (Sirius Red staining); MMP-2/9 activity via zymography; and VEGF protein levels in wound fluid. Oxidative stress markers (8-OHdG, MDA) and antioxidant enzyme activity (SOD1, catalase) are secondary endpoints in aging models.

GHK-Cu has a well-characterised safety profile in preclinical models. Copper toxicity is a theoretical concern at very high concentrations but has not been observed at research-relevant doses in published studies. The peptide's high copper-binding affinity (Ka ~10¹⁷ M⁻¹) means free cupric ion release is minimal. No significant adverse effects are reported in published animal studies.

Protocol Overview

This protocol outlines the research parameters used in published GHK-Cu skin aging and wound healing studies, drawn from the scientific literature. It is intended as a reference for researchers designing GHK-Cu investigations and is not a clinical treatment protocol.

Research goal: Skin rejuvenation, collagen synthesis, wound healing acceleration Primary peptide: GHK-Cu (Copper Tripeptide-1) Duration: 12 weeks Model systems in literature: In vitro fibroblast cultures, ex vivo skin biopsies, rodent skin wound models, aged skin gene expression studies

Scientific Context

GHK-Cu is the most studied peptide for skin aging research. Its documented effects on collagen synthesis (types I, III, VI), antioxidant gene expression (SOD1, catalase), angiogenesis (VEGF-A), and matrix remodeling (MMP-2/9) make it the benchmark peptide for dermal regeneration investigations. The landmark Pickart & Margolina (2018) gene atlas (PMID: 29987172) provides the mechanistic foundation for this protocol.

The 12-week duration reflects the timeline used in collagen turnover studies — collagen has a half-life of approximately 60–70 days, making sub-12-week observations insufficient to capture full remodeling effects.

Key Endpoints Used in Published Research

• Collagen density: Sirius Red staining of dermal biopsy sections
• Skin thickness: Ultrasound dermoscopy (20 MHz)
• Fibroblast activity: Procollagen type I C-peptide (PICP) ELISA
• Antioxidant status: SOD1 activity, MDA levels, 8-OHdG
• Angiogenesis markers: VEGF-A immunohistochemistry, capillary density count

Referenced Research

• [Pickart & Margolina 2018 — GHK-Cu Gene Regulation](/research/pickart-margolina-2018-ghk-cu-gene-regulation)
• GHK-Cu Monograph

Research Use Only · Not for human consumption · Consult a qualified researcher or physician before any protocol.